Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

BACKGROUND: People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV and HIV-negative individuals in...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Shabir A, Koen, Anthonet L, Izu, Alane, Fairlie, Lee, Cutland, Clare L, Baillie, Vicky, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Aley, Parvinder K, Bhikha, Sutika, Hermanus, Tandile, Horne, Elizea, Jose, Aylin, Kgagudi, Prudence, Lambe, Teresa, Masenya, Masebole, Masilela, Mduduzi, Mkhize, Nonhlanhla, Moultrie, Andrew, Mukendi, Christian K, Moyo-Gwete, Thandeka, Nana, Amit J, Nzimande, Ayanda, Patel, Faeezah, Rhead, Sarah, Taoushanis, Carol, Thombrayil, Asha, van Eck, Samuel, Voysey, Merryn, Villafana, Tonya L, Vekemans, Johan, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, Kwatra, Gaurav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372504/
https://www.ncbi.nlm.nih.gov/pubmed/34416193
http://dx.doi.org/10.1016/S2352-3018(21)00157-0

Ejemplares similares

Ejemplares similares